iBio, Inc.
Clinical trials sponsored by iBio, Inc., explained in plain language.
iBio, Inc.
IBIO
NYSE AMERICAN
A biotech company using plant-based technology to develop vaccines and therapeutics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New weight loss drug IBIO-600 enters first human trial Results expected May 2027 (estimated)